The Production Linked Incentive Scheme aims to build an Indian manufacturing base across 13 key sectors. What works. What doesn’t
On March 10, the $274 billion, Cupertino, California-based Apple Inc. announced it is starting production of the 5G-compatible iPhone 12 in India. It appeared like a routine announcement. After all, Apple has been assembling older generation iPhones in India through contract manufacturers since 2017. It wasn’t.
It might have been a small step for Apple but was a giant leap for Indian manufacturing. India’s new Production Linked Incentive (PLI) Scheme to reduce import dependence and promote local manufacturing had lured three of Apple’s Taiwanese original equipment manufacturers – Foxconnn Hon Hai, Wistron and Pegatron – to pump in millions of dollars to expand Indian facilities. They will move a step up from assembling imported parts here to making or sourcing more components locally. Like Apple, about 70 firms have shown interest in availing the PLI Scheme to set up manufacturing facilities in three key sectors: mobile and electronic components; pharma-APIs (active pharmaceutical ingredients); KSM (key starting materials) and medical devices.